| Title |
Published on |
Year |
| Cytological diagnostic features of late breast implant seromas. From reactive to anaplastic large cell lymphoma |
PLOS ONE |
2017 |
| In Reply to Adams and Kwee |
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
2017 |
| Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy |
JOURNAL OF CLINICAL ONCOLOGY |
2017 |
| Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study |
BRITISH JOURNAL OF HAEMATOLOGY |
2017 |
| Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study |
THE LANCET ONCOLOGY |
2017 |
| A MALT lymphoma prognostic index |
BLOOD |
2017 |
| Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma |
JOURNAL OF CLINICAL ONCOLOGY |
2017 |
| Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? |
EXPERT REVIEW OF HEMATOLOGY |
2017 |
| PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS |
22nd Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2017 |
| Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply |
THE LANCET ONCOLOGY |
2017 |
| EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP |
HAEMATOLOGICA |
2017 |
| Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper |
EUROPEAN JOURNAL OF HAEMATOLOGY |
2016 |
| The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma) |
PHYSICA MEDICA |
2016 |
| Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up |
ANNALS OF ONCOLOGY |
2016 |
| Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: Interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study |
HEMATOLOGICAL ONCOLOGY |
2016 |
| CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE CENTER ANALYSIS OF THE RISK FACTORS AND THE IMPACT OF CNS PROPHYLAXIS IN THE RITUXIMAB ERA |
21st Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2016 |
| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) |
THE ONCOLOGIST |
2015 |
| Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma |
BLOOD |
2015 |
| Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL) |
LEUKEMIA & LYMPHOMA |
2015 |
| PET scanner clinical trial qualification for worldwide onco-hematological studies |
LEUKEMIA & LYMPHOMALEUKEMIA & LYMPHOMA |
2015 |
